HEALTH
FDA Panel Backs Peptides As Scientists Warn Of Risks
Federal health advisers narrowly recommended easing access to wellness peptides, clashing directly with FDA staff warnings.
An FDA advisory panel narrowly recommended easing access to several peptide drugs popular with wellness influencers on Thursday. The decision sets up a clash with FDA staff scientists, who warned there is insufficient evidence regarding the safety and effectiveness of the peptides.
- A federal health advisory panel narrowly voted to recommend expanded access to popular wellness peptides.
- FDA staff scientists warned that evidence for the peptides' safety and effectiveness remains insufficient.
- Officials raised conflict of interest concerns regarding panel members who worked for peptide-related businesses and clinics.
WHY THIS MATTERSIf you rely on these trendy wellness compounds or buy them through alternative clinics, shifting federal rules will directly impact availability, pricing, and how easily you can get your hands on them.